Advice - reimburse mirikizumab (Omvoh®) for Crohn's disease
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse mirikizumab (Omvoh®) from the basic healthcare package. This medicinal product can be used in certain patients with Crohn's disease. The reason for this advice was the placing of the medicinal product in the so-called ‘lock procedure’ for expensive medicinal products’.
This is the tenth medicinal product the Medicines Evaluation Board and the National Health Care Institute have assessed in a parallel procedure.
Mirikizumab is intended for people with Crohn's disease
Mirikizumab is the active substance. The brand name is Omvoh®. The medicine is a solution for injection
that can be used in adults with moderately to severely active Crohn's disease. Crohn's disease is a chronic inflammatory disease of the intestines. Chronic means it does not go away. In most patients with Crohn's disease, the small intestines, the large intestines or the rectum are inflamed. The most common symptoms are abdominal pain, diarrhoea and fatigue. These patients have moderately to severely active Crohn's disease and have not (adequately) responded to, or have been intolerant to, a biological medicine.
Advice from the National Health Care Institute on the reimbursement of mirikizumab
The National Health Care Institute advises the Minister of VWS to reimburse mirikizumab (Omvoh®) from the basic healthcare package. Because the medicinal product has an equal value as the standard treatment, we also recommend an equal price.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The Minister of Health, Welfare and Sport (VWS) asks the National Health Care Institute to carry out an assessment. The final decision as to whether or not reimbursement from the basic healthcare package will take place lies with the Minister.
Lock procedure for expensive medicinal products
The Minister has placed mirikizumab for this indication in the lock procedure for expensive medicinal products. A medicinal product in this lock procedure will not be eligible for reimbursement from the basic health care package until:
- there is a positive package advice from the National Health Care Institute;
- there are arrangements and safeguards for appropriateness in place;
- price reductions have been successfully negotiated with the manufacturer.
For more information, see the page ‘Lock procedure for expensive medicinal products’.
Parallel procedure Medicines Evaluation Board-National Health Care Institute
The assessment of mirikizumab was conducted in the parallel procedure of the Medicines Evaluation Board and the National Health Care Institute. In this procedure, they simultaneously assess a medicine’s admission to the Dutch market and the reimbursement from the basic healthcare package. This will give patients access to new medicines as soon as possible.